Table 1

Patient characteristics
Case # Diagnosis Age (years) Gender Stage B symptom EBER-1
1 NS 28 F II - -
2 NS 44 F II - +
3 NS 30 M I - -
4 NS 27 F II - -
5 NS 18 F II - -
6 NS 27 M II + -
7 NS 22 M IV - -
8 NS 57 M III - -
9 NS 48 M III -
10 MC 29 M IV - -
11 NS 34 M II - -
12 NS 22 F II - -
13 NS 14 F I - -
14 MC 53 M I - -
15 MC 59 M I - +
16 MC 42 M III + -
17 MC 50 M II - -
18 MC 29 F II + +
19 MC 50 M I - +
20 NS 39 F IV - -
21 NS 22 F II + -
22 MC 55 F I - +
23 LD 59 F I - -
24 NS 32 F II + -
25 NS 16 M III - -
26 NS 24 F III - -
27 NS 20 M II - -
28 MC 67 F IV + +
29 NS 26 F II - -
30 MC 73 F IV - +
31 MC 74 F II - -
32 LR 81 F II - -
33 MC 75 F III + +
34 MC 33 F III + -
35 MC 62 F III - +
36 MC 53 M II - +
37 LR 72 M II - +
38 NS 16 F II - -
39 NS 36 F II + -
40 NS 16 F II - -
41 LR 48 M III + +
42 LD 67 M I - +
43 NS 27 F II - -
44 NS 43 F II - -
45 NS 64 M II + -
46 NS 66 F III - +
47 NS 24 F II - +

NS, Nodular sclerosis cHL; MC, Mixed cellularity cHL; LD, Lymphocyte-depleted cHL; LR, lymphocyte-rich cHL.

Nomoto et al.

Nomoto et al. BMC Cancer 2012 12:457   doi:10.1186/1471-2407-12-457

Open Data